secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001070081-23-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q1 rev $220M (+48% YoY), DMD $170M; FY23 guidance reaffirmed
-----------------------------------------------------------------------------

- Total revenue $220.4M vs $148.7M YoY (+48%); net product revenue $187.6M vs $129.8M.
- Translarna net revenue $115.1M (+45% YoY); Emflaza $54.6M (+12% YoY); Evrysdi royalty $30.8M (+63%).
- GAAP net loss $139.0M vs $126.7M; cash $286.3M at quarter-end vs $410.7M at Dec 31.
- Reaffirmed FY2023 total revenue guidance $940M-$1.0B; DMD franchise $545-565M.
- Four clinical readouts expected in Q2 2023, incl. registration trials for sepiapterin (PKU), vatiquinone (FA & mito disease), and PTC518 (HD) interim data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/0001070081-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000026/tmb-20230427x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer